Equities researchers at Maxim Group upped their target price on shares of Medivation (NASDAQ:MDVN) from $92.00 to $112.00 in a research report issued on Monday, AR Network reports. The firm currently has a “buy” rating on the stock. Maxim Group’s price objective suggests a potential upside of 65.29% from the stock’s previous close.
Medivation (NASDAQ:MDVN) opened at 67.76 on Monday. Medivation has a 52 week low of $41.89 and a 52 week high of $88.20. The stock has a 50-day moving average of $77.07 and a 200-day moving average of $65.60. The company’s market cap is $5.172 billion.
Medivation (NASDAQ:MDVN) last posted its quarterly earnings results on Thursday, February 27th. The company reported $0.03 EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.08) by $0.11. The company had revenue of $96.61 million for the quarter, compared to the consensus estimate of $72.68 million. During the same quarter in the prior year, the company posted ($0.43) earnings per share. The company’s quarterly revenue was up 160.0% on a year-over-year basis. Analysts expect that Medivation will post $0.79 EPS for the current fiscal year.
A number of other firms have also recently commented on MDVN. Analysts at UBS AG cut their price target on shares of Medivation from $93.00 to $85.00 in a research note on Monday, March 3rd. They now have a “buy” rating on the stock. Separately, analysts at Aegis reiterated a “buy” rating on shares of Medivation in a research note on Friday, February 28th. Finally, analysts at Cowen and Company downgraded shares of Medivation from a “market perform” rating to an “underperform” rating in a research note on Friday, February 28th. Two investment analysts have rated the stock with a sell rating, four have given a hold rating and nine have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus target price of $91.13.
Medivation, Inc is a biopharmaceutical company focused on the development and commercialization of novel therapies.
Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.